Clinical trials: Major Depressive Disorder, Healthy Volunteer
Major Depressive Disorder
A Study of the Effect of LY2216684 on Lorazepam
The purpose of this study is to determine how much lorazepam gets into the blood and how long it takes the body to get rid of it when given together with LY2216684.
- Trial name
- NCT01275144
- Testing
- LY2216684, Lorazepam
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in…
- Trial name
- NCT03357796
- Testing
- LY03005, Pristiq
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Depressive Disorder, Major
Effects of Tryptophan Depletion on Brain Processing of Emotions in Patients With Mood Disorders
This study will investigate how the brain process emotions in healthy people and in patients who have major depression in order to better understand the causes of depression.
- Trial name
- NCT00097175
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Depressive Disorder, Major
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects
This is a Phase 1, conventional, double-blind, placebo-controlled, single-center clinical study comprised of 2 segments (Segment 1 and Segment 2) in which single and multiple doses of SUVN-911 or placebo will be orally…
- Trial name
- SUVN-911 (NCT03155503)
- Testing
- SUVN-911
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Healthy
A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers
This study will evaluate the safety, tolerability and pharmacokinetics of BCI-838, its metabolite BCI-632 and several new pro-drugs in healthy male subjects.
- Trial name
- NCT01546051
- Testing
- BCI-838, BCI-1038, BCI-1206 & BCI-1283
- Where
- Netherlands
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- BrainCells Inc.
Major Depressive Disorder (MDD)
Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People
Major depressive disorder was shown to be associated with pathological alterations within neurotransmitter systems of the brain.
- Trial name
- NCT06675851
- Testing
- WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline, Cipralex (escitalopram)
- Where
- Austria
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Apathy, Behavioral Variant Frontotemporal Dementia (bvFTD)
Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System
Apathy is defined as a quantitative reduction in voluntary and goal-directed behavior. To address this, the investigators propose an ethological approach to assess apathy objectively and quantitatively by observing patients in…
- Conditions
- Apathy, Behavioral Variant Frontotemporal Dementia (bvFTD), Disinhibition, Depression - Major Depressive Disorder
- Trial name
- ECOCAPTURE (NCT03272230)
- Testing
- ECOCAPTURE, Cognitive and Behavioral experimental tasks, Neuropsychological assessment
- Where
- France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Depression, Depressive Disorder
Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects
The purpose of this study is to evaluate the effects of multiple doses of DVS SR and duloxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00366652
- Testing
- desvenlafaxine SR, desipramine, duloxetine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder, Major
A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects
The study involves a single oral dose of 18 mg (2 x 9mg tablets) LY2216684 taken on 2 occasions, once with activated charcoal and once without activated charcoal.
- Trial name
- NCT01389752
- Testing
- LY2216684, Activated Charcoal
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline
LY2216684 is being studied as adjunctive treatment for major depressive disorder (MDD) in participants who are partial responders to selective serotonin reuptake inhibitors (SSRIs).
- Trial name
- NCT01250873
- Testing
- LY2216684, Sertraline
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder (MDD)
Scopolamine in Healthy Volunteers
This single-site clinical trial is an open-label study to identify the safety and pharmacokinetics of DPI-386 Nasal Gel (intranasal scopolamine gel) and IV Scopolamine.
- Trial name
- NCT03874130
- Testing
- Scopolamine
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Repurposed Therapeutics, Inc.
Epilepsy, Epilepsy, Temporal Lobe
GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major Depression
Objective: To study the relative balance of GABA (A) binding potential and glutamate utilization in subjects with localization-related epilepsy with and without depression, subjects with major depressive disorder alone, and in…
- Conditions
- Epilepsy, Epilepsy, Temporal Lobe, Depression, Depressive Disorder, Major
- Trial name
- NCT00931619
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Major Depressive Disorder, Healthy
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients
The primary purpose of this protocol is to compare PDE4 levels before and after starting a selective serotonin reuptake inhibitor (SSRI) sertraline, citalopram or escitalopram in unmedicated depressed patients.
- Trial name
- NCT00369798
- Testing
- PET scan, Rolipram
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Depressive Disorder, Major
Effects of Escitalopram on the Sleep EEG Power in Patients With Major Depressive Disorder
The main objective was to compare the differences of PSG parameters and plasma melatonin levels before and after treatment with escitalopram for 8 weeks.
- Trial name
- NCT04013464
- Testing
- Escitalopram
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Peking University Sixth Hospital
Healthy
A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder
Double-blind, placebo-controlled, multiple ascending oral dose evaluation of the safety, tolerability, and pharmacokinetics of DSP 1053 and its metabolites in healthy subjects and in subjects with major depressive disorder
- Trial name
- MAD (NCT01774747)
- Testing
- DSP-1053
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depressive Disorder
A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression
The purpose of this study is to evaluate the safety of PDC-1421 Capsule in healthy subject, find the effective adequate dose for the next stage of the study, and accumulate information of possible mechanism of its anti-depressive…
- Trial name
- NCT01774045
- Testing
- PDC-1421
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BioLite, Inc.
Major Depressive Disorder
A Study of LY03005 vs Pristiq
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in…
- Trial name
- NCT03733574
- Testing
- LY03005, Pristiq
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Depression
Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)
This study is designed to characterize the regional distribution of [11C] ABP688 in brain by positron emission tomography (PET).
- Trial name
- NCT01528241
- Testing
- ABP688
- Where
- 2 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals